COMP <GO>
MRNA vs ABBV // FREE CASH FLOW YIELD
Moderna Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MRNA 3
— ABBV 11
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
fcf-yield
-2.32%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | 70.20% | -14.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | 29.00% | -63.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -2.32% | 3.47% | -5.79 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -39.90% | 8.60% | -48.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.07 | 5.33 | +9.74 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | MRNA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 72.8 | -15.45 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 113.1x | -81.10 | MRNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $513.86B | -$424.93B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | ABBV REV | MRNA GROSS % | ABBV GROSS % | MRNA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $61.16B | 55.3% | 70.2% | -$2.06B | $17.82B |
| FY 2024 | $3.24B | $56.33B | 54.8% | 70.0% | -$4.05B | $17.83B |
| FY 2023 | $6.85B | $54.32B | 44.0% | 44.0% | -$3.43B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
ABBV // BETA 1.15